Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2020

View Archived Issues

Helping hand for protein sorting prevents AD

Mutant TP53 affects fat metabolism

Skin-deep defense may be good enough for arboviruses

New phase I trial studies monoclonal antibody CIS-43LS against malaria

Topline data from phase III VELOS-2 study of HL-036

Blueberry Therapeutics receives IND clearance from the FDA for BB-2603

TRuE-AD2 pivotal phase III study of ruxolitinib cream meets primary endpoint

First patient dosed in phase I study of SY-5609

FDA approves first human trials of Myeliviz for PET imaging in MS

V-4020, a novel VEEV vaccine with increased safety and stability

cis-Regulatory elements of the FOXA1 plexus as therapeutic targets in prostate cancer

Results from phase I/II COMPOSER study of crovalimab

Janssen presents phase II results for daratumumab in relapsed AL amyloidosis

Melanocortin MC2 receptor antagonists disclosed by Crinetics Pharmaceuticals

Saint Louis University, Indalo Therapeutics patent integrin alphavbeta1/alpha5beta1 antagonists

Idorsia Pharmaceuticals discovers OX1/OX2 receptor antagonists

Servier, Vernalis identify new ubiquitin carboxyl-terminal hydrolase 7 inhibitors

Nuclear receptor ROR-gamma antagonists discovered at Sunshine Lake Pharma

Trovagene presents update on phase Ib/II trial of onvansertib

Feisty old folks: Sprightly genomes bring insights into healthy aging, early-onset illness

Enrollment open in first-in-human study of CC-97540 in NHL

Phase II study of AKCEA-ANGPTL3-LRx meets primary endpoint of significant triglyceride lowering

Clover begins development of recombinant subunit vaccine for 2019-nCoV

CytoDyn explores use of leronlimab for novel coronavirus

Avacta demonstrates proof of concept for TMAC platform in animal model of cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...